58 results on '"deferiprone"'
Search Results
2. Ferritin and Iron Burden in SAH sIRB
3. Deferiprone to Delay Dementia (The 3D Study)
4. Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children (START)
5. Study of Parkinson's Early Stage With Deferiprone (SKY)
6. Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
7. Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
8. Compassionate Use of Deferiprone in Patients With PKAN
9. Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis (FAIR-ALS II)
10. Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)
11. Iron Chelation in the Prevention of Secondary Degeneration After Stroke (CHEL-IC)
12. Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients
13. Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (FIRST)
14. Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload (TWICE)
15. Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
16. Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
17. Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration (TIRCON-EXT)
18. A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease (DeferipronPD)
19. Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes (LymphoEnergy)
20. Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
21. Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
22. Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
23. A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment
24. Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
25. Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients (SAFEFAIRALS)
26. Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration
27. Pharmacokinetic Study of Deferiprone in Paediatric Patients (DEEP-1)
28. Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
29. Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects
30. Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers
31. Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers
32. Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers
33. Efficacy Study in Removing Excess Iron From the Heart
34. Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
35. An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
36. Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)
37. A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
38. Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
39. An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
40. An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
41. Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients
42. Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects
43. Role of Vitamin C to Augment Iron Chelation With DFP or DFX
44. Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
45. Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
46. Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease (FAIR-PARK-I)
47. Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients
48. Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
49. Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
50. Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.